A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Diacerein (Primary) ; Febuxostat
- Indications Gout
- Focus Proof of concept; Therapeutic Use
- Sponsors TWi Biotechnology
- 05 Apr 2017 Status changed from active, no longer recruiting to completed.
- 27 Jun 2016 According to a TWi Biotechnology, Inc., media release, the Company expects to report top-line results from this study in the fourth quarter of 2016.
- 27 Jun 2016 Status changed from recruiting to active, no longer recruiting, according to a TWi Biotechnology, Inc., media release.